![]() This study shows that when symptoms are present in inflammatory disease patients, they could be important indicators of vaccine response. They found that a higher number of reported symptoms was associated with higher antibody titers - each increase of one symptom (such as headache, fatigue, or muscle ache) was associated with a 15.9 percent increase in antibody levels. Researchers studied the outcomes of the COVID-19 vaccines in 134 patients with chronic inflammatory disease and 44 healthy controls. Interestingly, another study showed that side effects in certain patients might correlate with vaccine effectiveness. (Less than 1 percent reported severe symptoms such as throat closing, wheezing, fainting, chest pain, difficulty breathing, bleeding, and swelling of the eyes, lips, or other parts of the body.) The data demonstrate that rheumatology patients experience local or systemic adverse event post-SARS-CoV-2 vaccination at rates similar to estimates from the vaccine clinical trial data. ![]() Pain at the injection site (45.3 percent).Most patients had received two vaccine doses.Īdverse events (symptoms within one week of the vaccine that were not attributed to systemic rheumatic disease flares) at the first or second dose were reported by 73.3 percent of respondents. Meanwhile, in another study presented at the ACR Convergence 2021, researchers surveyed a total of 1,852 rheumatology outpatients in New York City who had received at least one COVID-19 vaccine dose (53.9 percent Pfizer, 44.4 percent Moderna, 1.4 percent Johnson & Johnson vaccine, and 0.3 percent AstraZeneca). This study may provide reassurance for those who are concerned about experiencing adverse effects or disease flares after vaccination. Only a small group of patients (5 percent) reported a deterioration in their autoimmune disease after vaccination. Severe adverse events were rare among the patients and controls (1 percent versus 0 percent). The majority of patients (56 percent) and controls (58 percent) experienced at least one mild adverse event - and a minority experienced at least one moderate adverse event (23 percent versus 21 percent, respectively). (AstraZeneca and Pfizer vaccines were the most common vaccines in both groups.) In a new study presented at ACR Convergence 2021, 501 patients in the Netherlands with systemic autoimmune diseases and 184 healthy controls were vaccinated against COVID-19, then surveyed about any side effects they experienced. We now have plenty of data that shows that people with autoimmune and inflammatory diseases do not have a higher risk of experiencing side effects from vaccination than the general population. Here, you’ll find a round-up of notable recent studies about the COVID-19 vaccines, many of which were just presented at the annual meeting of the American College of Rheumatology, ACR Convergence 2021.Ĭheck out this separate round-up on the latest information on COVID-19 (infection rates, complications, and more) in rheumatic disease patients.įor more research breakthroughs from ACR 2021, check out our main guide: 100+ Arthritis & Rheumatic Disease Updates You Need to Know. This may help provide better protection to immunocompromised and high-risk people going forward. Though there was a disconcerting lack of data on immunocompromised conditions when the vaccine first became available last year, emerging research is now providing much more information on the COVID-19 vaccine in people with rheumatic diseases. Other important issues include understanding side effects, the risk for disease flares, vaccine hesitancy, and more. Researchers and patients have been seeking answers about how taking immunosuppressive medication may affect the vaccine’s effectiveness. Since the rollout of the COVID-19 vaccine over the past year, there has been a surge in important research on their impact on people with rheumatic diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |